open access

Ahead of print
Short communication
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-11-17
Get Citation

Long-term follow-up of pediatric patients with EBV-related post-transplant lymphoproliferative disorder

Przemysław Gałązka1, Małgorzata Szafrańska2, Kamila Jaremek1, Dorota Rutkowska3, Krzysztof Czyżewski1, Robert Dębski1, Monika Richert-Przygońska1, Tomasz Grzybowski4, Joanna Konieczek1, Jan Styczynski1
DOI: 10.5603/AHP.a2021.0099
Affiliations
  1. Department of Pediatric Hematology and Oncology, Collegium Medicum, Bydgoszcz, Poland
  2. Department of Endocrinology and Diabetology, Collegium Medicum, Nicolaus Copernicus University, Jurasz University Hospital 1, Bydgoszcz, Poland
  3. Laboratory for Medical Education, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
  4. Department of Forensic Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

open access

Ahead of print
SHORT COMMUNICATION
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-11-17

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

hematopoietic cell transplantation, children, survival, relapse, endocrinological complications

About this article
Title

Long-term follow-up of pediatric patients with EBV-related post-transplant lymphoproliferative disorder

Journal

Acta Haematologica Polonica

Issue

Ahead of print

Article type

Short communication

Published online

2021-11-17

DOI

10.5603/AHP.a2021.0099

Keywords

hematopoietic cell transplantation
children
survival
relapse
endocrinological complications

Authors

Przemysław Gałązka
Małgorzata Szafrańska
Kamila Jaremek
Dorota Rutkowska
Krzysztof Czyżewski
Robert Dębski
Monika Richert-Przygońska
Tomasz Grzybowski
Joanna Konieczek
Jan Styczynski

References (12)
  1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999; 94(7): 2208–2216.
  2. Styczyński J. Infectious complications in children and adults with hematological malignancies. Acta Haematol Pol. 2019; 50(3): 167–173.
  3. Styczyński J. ABC of viral infections in hematology: focus on herpesviruses. Acta Haematol Pol. 2019; 50(3): 159–166.
  4. Styczyński J. Limfadenopatia u dzieci i dorosłych: zasady postępowania diagnostycznego. Acta Haematol Pol. 2019; 50(3): 98–102.
  5. Styczynski J, Reusser P, Einsele H, et al. Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009; 43(10): 757–770.
  6. Styczynski J, van der Velden W, Fox CP, et al. Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803–811.
  7. Styczynski J, Gil L, Tridello G, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013; 57(6): 794–802.
  8. Styczyński J, Kałwak K, Czyżewski K, et al. Results of therapy with anti-CD20 antibodies in EBV-related post-transplant lymphoproliferative disorder. Post Nauk Med. 2014; 27(4): 261–264.
  9. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579–586.
  10. Kinch A, Hallböök H, Arvidson J, et al. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. Leuk Lymphoma. 2018; 59(5): 1172–1179.
  11. Salooja N, Shoham Z, Dalle JH. Endocrine disorders, fertility and sexual health. In: Carreras E, Dufour C, Mohty M, Kroger N. ed. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Springer, Cham 2019: 421–427.
  12. Styczynski J, Tridello G, Gil L, et al. Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematol Pol. 2020; 51(2): 73–80.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl